Skip to content

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

By API User

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential … Continued

Forget resolutions: Why ‘burnout blockers’ are essential in 2026

By API User

Key Facts: 70% of working Australians experienced burnout in 2025, with 41% reporting constant stress and one-third at high mental health risk Burnout specialist Nick Orchard warns against focusing on recovery rather than prevention, with workplace burnout costing Australian businesses $14 billion Early warning signs include needing external validation, information overload, relying on stimulants, and … Continued

Peer-Reviewed Publication in Leading Journal Validates BlinkLab’s Autism Assessment Technology, Providing Support for Future Clinical Adoption

By API User

5 January 2026 – Perth, Western Australia | BlinkLab Limited (ASX:BB1) today announced that a peer-reviewed scientific paper validating its smartphone-based neurobehavioural assessment technology has been published in Autism Research, one of the most prestigious and widely cited journals in the field of neurodevelopmental disorders.  The publication provides independent scientific validation of BlinkLab’s core technology … Continued

SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement

By API User

BEIJING–BUSINESS WIRE– Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the … Continued

Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report

By API User

BEIJING–BUSINESS WIRE– Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the … Continued

Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 2026

By API User

Due to an extraordinary global response of over 134,000 registrations from 214 countries, the submission deadline has been extended. Nurses worldwide can submit their nominations via www.asterguardians.com DUBAI, United Arab Emirates–BUSINESS WIRE– The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension … Continued

UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy

By API User

The newly licensed intrathecal gene therapy expands life-changing treatment options for children and adults affected by SMA DUBAI, United Arab Emirates–BUSINESS WIRE– Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private … Continued

Memphasys Secures CE Mark Approval for Felix(TM) System, Marking Commercial Inflection Point and Activating Global Growth Strategy

By API User

HIGHLIGHTS CE Mark approval achieved for the Felix™ System under EU MDR, unlocking full commercial deployment across Europe and other CE-recognised international markets. Immediate Access to ~A$50+ million (€29+ million) Felix™ Addressable Market Binding, multi-year commercial agreements now activated, including: a five-year European commercial agreement with CFA Italia valued at a minimum of ~A$925,000, and a … Continued